{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:46:19Z","timestamp":1787067979046,"version":"build-2736575974"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Parathyroid carcinoma (PC) is an orphan malignancy accounting for only ~1% of all cases with primary hyperparathyroidism. The localization of recurrent PC is of critical importance and can be exceedingly difficult to diagnose and sometimes futile when common sites of recurrence in the neck and chest cannot be confirmed. Here, we present the diagnostic workup, molecular analysis and multimodal therapy of a 46-year old woman with the extraordinary manifestation of abdominal lymph node metastases 12 years after primary diagnosis of PC. The patient was referred to our endocrine tumor center in 2016 with the aim to localize the tumor causative of symptomatic biochemical recurrence. In view of the extensive previous workup we decided to perform [18F]FDG-PET-CT. A pathological lymph node in the liver hilus showed slightly increased FDG-uptake and hence was suspected as site of recurrence. Selective venous sampling confirmed increased parathyroid hormone concentration in liver veins. Abdominal lymph node metastasis was resected and histopathological examination confirmed PC. Within four months, the patient experienced biochemical recurrence and based on high tumor mutational burden detected in the surgical specimen by whole exome sequencing the patient received immunotherapy with pembrolizumab that led to a biochemical response. Subsequent to disease progression repeated abdominal lymph node resection was performed in 10\/2018, 01\/2019 and in 01\/2020. Up to now (12\/2020) the patient is biochemically free of disease. In conclusion, a multimodal diagnostic approach and therapy in an interdisciplinary setting is needed for patients with rare endocrine tumors. Molecular analyses may inform additional treatment options including checkpoint inhibitors such as pembrolizumab.<\/jats:p>","DOI":"10.3389\/fendo.2021.643328","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T02:55:54Z","timestamp":1616468154000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management"],"prefix":"10.3389","volume":"12","author":[{"given":"Christina","family":"Lenschow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmina Teresa","family":"Fuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kircher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Kickuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Reibetanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Wiegering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Stenzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"H\u00fcbschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph Thomas","family":"Germer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Fr\u00f6hling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Schlegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kroiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1080\/0284186X.2017.1306103","article-title":"A nationwide study on parathyroid carcinoma","volume":"56","author":"Ryhanen","year":"2017","journal-title":"Acta Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01665308","article-title":"Diagnosis and treatment of patients with parathyroid carcinoma: an update and review","volume":"15","author":"Obara","year":"1991","journal-title":"World J Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22599","article-title":"Trends in the incidence and treatment of parathyroid cancer in the United States","volume":"109","author":"Lee","year":"2007","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000491039","article-title":"Parathyroid Carcinoma","volume":"51","author":"Cetani","year":"2019","journal-title":"Front Horm Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1571","article-title":"Parathyroid carcinoma: a 43-year outcome and survival analysis","volume":"96","author":"Harari","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-010-0042-6","article-title":"Challenges and pitfalls in the management of parathyroid carcinoma: 17-year follow-up of a case and review of the literature","volume":"1","author":"Witteveen","year":"2010","journal-title":"Horm Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3541131","article-title":"Clinical Presentation, Treatment, and Outcome of Parathyroid Carcinoma: Results of the NEKAR Retrospective International Multicenter Study","author":"Lenschow","year":"2020","journal-title":"Ann Surg"},{"key":"B8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40618-016-0447-3","article-title":"Update on parathyroid carcinoma","volume":"39","author":"Cetani","year":"2016","journal-title":"J Endocrinol Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-011-0344-y","article-title":"Parathyroid carcinoma presenting as normocalcemic hyperparathyroidism","volume":"30","author":"Campenni","year":"2012","journal-title":"J Bone Miner Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.7076","article-title":"Clinical characteristics and treatment outcomes of parathyroid carcinoma: A retrospective review of 234 cases","volume":"14","author":"Wang","year":"2017","journal-title":"Oncol Lett"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.3390\/cancers11111676","article-title":"Parathyroid Cancer: A Review","volume":"11","author":"Machado","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/030089168707300218","article-title":"Apparently nonfunctioning metastases of parathyroid carcinoma","volume":"73","author":"Manente","year":"1987","journal-title":"Tumori"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2014","article-title":"Unusual case of solitary functioning bone metastasis from a \u201cparathyroid adenoma\u201d: imagiologic diagnosis and treatment with percutaneous vertebroplasty\u2013case report and literature review","volume":"98","author":"Qiu","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM195303052481007","article-title":"WEEKLY clinicopathological exercises; parathyroid carcinoma with hyperparathyroidism and with metastases to liver","volume":"248","year":"1953","journal-title":"N Engl J Med"},{"key":"B15","article-title":"WHO classification of tumours of endocrine organs by International Agency for Research","volume-title":"Cancer","author":"Lloyd","year":"2017"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e10114","DOI":"10.1002\/jbm4.10114","article-title":"Recurrent Metastasized Parathyroid Carcinoma-Long-Term Remission After Combined Treatments With Surgery, Radiotherapy, Cinacalcet, Zoledronic Acid, and Temozolomide","volume":"3","author":"Storvall","year":"2019","journal-title":"JBMR Plus"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v2.i10.348","article-title":"FDG-PET\/CT and parathyroid carcinoma: Review of literature and illustrative case series","volume":"2","author":"Evangelista","year":"2011","journal-title":"World J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3130-6","article-title":"(1)(8)Fluorocholine PET\/CT in parathyroid carcinoma: a new tool for disease staging","volume":"42","author":"Deandreis","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000001652","article-title":"18F-Fluorocholine, 18F-FDG, and 18F-Fluoroethyl Tyrosine PET\/CT in Parathyroid Cancer","volume":"42","author":"Hatzl","year":"2017","journal-title":"Clin Nucl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3238","article-title":"Whole-exome sequencing studies of parathyroid carcinomas reveal novel PRUNE2 mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with cell migration and invasion","volume":"100","author":"Yu","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.10.019","article-title":"Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence","volume":"38","author":"Passaro","year":"2020","journal-title":"Cancer Cell"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.643328\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T02:55:57Z","timestamp":1616468157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.643328\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":21,"alternative-id":["10.3389\/fendo.2021.643328"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.643328","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]},"article-number":"643328"}}